Pulmonx Corporation (LUNG)
LUNG Stock Price Chart
Explore Pulmonx Corporation interactive price chart. Choose custom timeframes to analyze LUNG price movements and trends.
LUNG Company Profile
Discover essential business fundamentals and corporate details for Pulmonx Corporation (LUNG) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
1 Oct 2020
Employees
291.00
Website
https://pulmonx.comCEO
Glendon E. French
Description
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
LUNG Financial Timeline
Browse a chronological timeline of Pulmonx Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Jul 2026
EPS estimate is -$0.28, while revenue estimate is $22.39m.
Earnings released on 29 Apr 2026
EPS came in at -$0.33 matching the estimated -$0.33, while revenue for the quarter reached $20.59m , beating expectations by +0.76%.
Earnings released on 4 Mar 2026
EPS came in at -$0.25 surpassing the estimated -$0.39 by +35.90%, while revenue for the quarter reached $22.60m , beating expectations by +4.00%.
Earnings released on 12 Nov 2025
EPS came in at -$0.34 surpassing the estimated -$0.40 by +15.00%, while revenue for the quarter reached $21.50m , missing expectations by -1.04%.
Earnings released on 30 Jul 2025
EPS came in at -$0.38 surpassing the estimated -$0.40 by +5.00%, while revenue for the quarter reached $23.86m , beating expectations by +1.99%.
Earnings released on 30 Apr 2025
EPS came in at -$0.36 surpassing the estimated -$0.37 by +2.70%, while revenue for the quarter reached $22.54m , beating expectations by +2.29%.
Earnings released on 19 Feb 2025
EPS came in at -$0.33 surpassing the estimated -$0.45 by +26.67%, while revenue for the quarter reached $23.77m , beating expectations by +6.61%.
Earnings released on 30 Oct 2024
EPS came in at -$0.36 surpassing the estimated -$0.43 by +16.28%, while revenue for the quarter reached $20.39m , missing expectations by -8.55%.
Earnings released on 31 Jul 2024
EPS came in at -$0.39 surpassing the estimated -$0.41 by +4.88%, while revenue for the quarter reached $20.78m , beating expectations by +3.24%.
Earnings released on 1 May 2024
EPS came in at -$0.36 surpassing the estimated -$0.43 by +16.28%, while revenue for the quarter reached $18.85m , beating expectations by +5.39%.
Earnings released on 21 Feb 2024
EPS came in at -$0.36 surpassing the estimated -$0.39 by +7.69%, while revenue for the quarter reached $19.28m , beating expectations by +5.52%.
Earnings released on 30 Oct 2023
EPS came in at -$0.39 surpassing the estimated -$0.45 by +13.33%, while revenue for the quarter reached $17.67m , beating expectations by +7.80%.
Earnings released on 2 Aug 2023
EPS came in at -$0.43 matching the estimated -$0.43, while revenue for the quarter reached $17.19m , beating expectations by +8.41%.
Earnings released on 2 May 2023
EPS came in at -$0.42 surpassing the estimated -$0.43 by +2.33%, while revenue for the quarter reached $14.54m , beating expectations by +7.75%.
Earnings released on 22 Feb 2023
EPS came in at -$0.38 surpassing the estimated -$0.41 by +7.32%, while revenue for the quarter reached $15.43m , beating expectations by +10.35%.
Earnings released on 3 Nov 2022
EPS came in at -$0.38 surpassing the estimated -$0.40 by +5.00%, while revenue for the quarter reached $13.50m , missing expectations by -9.59%.
Earnings released on 2 Aug 2022
EPS came in at -$0.40 surpassing the estimated -$0.41 by +2.44%, while revenue for the quarter reached $13.95m , beating expectations by +1.31%.
Earnings released on 3 May 2022
EPS came in at -$0.43 falling short of the estimated -$0.37 by -16.22%, while revenue for the quarter reached $10.79m , beating expectations by +16.44%.
Earnings released on 23 Feb 2022
EPS came in at -$0.35 matching the estimated -$0.35, while revenue for the quarter reached $13.71m , missing expectations by -3.75%.
Earnings released on 2 Nov 2021
EPS came in at -$0.28 surpassing the estimated -$0.37 by +24.32%, while revenue for the quarter reached $13.26m , beating expectations by +0.61%.
Earnings released on 3 Aug 2021
EPS came in at -$0.34 surpassing the estimated -$0.38 by +10.53%, while revenue for the quarter reached $12.20m , meeting expectations.
LUNG Stock Performance
Access detailed LUNG performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
